In a report released today, Stephen Laws from Raymond James maintained a Buy rating on MFA Financial (MFA – Research Report), with a price target of $15.50. The company’s shares closed last Friday at $12.13.
Laws covers the Financial sector, focusing on stocks such as MFA Financial, ACRES Commercial Realty, and Ready Capital. According to TipRanks, Laws has an average return of 15.7% and a 65.33% success rate on recommended stocks.
MFA Financial has an analyst consensus of Moderate Buy, with a price target consensus of $14.95.
Based on MFA Financial’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $100.37 million. In comparison, last year the company earned a revenue of $74.62 million and had a net profit of $66.71 million
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MFA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MFA Financial, Inc. operates as a real estate investment trust, which engages in the business of investment, on a leveraged basis, in residential mortgage assets including agency mortgage-backed securities, non-agency mortgage-backed securities, and residential whole loans. The company was founded by Stewart Zimmerman on July 24, 1997 and is headquartered in New York, NY.
Read More on MFA:
- Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
- Mizuho Securities Keeps Their Buy Rating on Life Time Group Holdings (LTH)
- HeartCore Reports Second Quarter 2022 Financial Results
- Duck Creek Technologies named as a Dominant Provider for its claims management solution by Aite-Novarica Group
- Morgan Stanley Remains a Sell on Genmab (GMAB)